Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ORIC
ORIC PHARMACEUTICALS, INC.
NASDAQ
$13.02
▼ DOWN 1.64% (-0.22)

KEY STATISTICS

Market Cap$1.37 B
52w High$14.93
52w Low$7.23
Dividend Yield—
Frequency—
P/E-9.65
Volume292.82K
Shares Out.103.52M

COMPANY

LEADERSHIP

Jacob Chacko
CHIEF EXECUTIVE
Jacob Chacko

COMPENSATION 2026

Salary$657,500
Stock Awards$826,000
Incentive Plan Pay$434,000
All Other Comp.$15,104
Total$5,567,164

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 24, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
111

PRICE TARGET

Target High$27.00
Target Low$15.00
Target Median$21.00
Target Consensus$21.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$13.02 ▼ DOWN 1.64% (−$0.22)
$12.97$13.05$13.129:30 AM9:32 AM9:35 AM9:37 AM9:39 AM9:42 AM9:44 AM13.02

About ORIC Pharmaceuticals, Inc.

https://www.oricpharma.com ↗

ORIC Pharmaceuticals, a clinical-stage biotech in South San Francisco, develops cancer therapies including ORIC-533, ORIC-944, and ORIC-114, targeting resistance mechanisms and collaborating with Voronoi and Mirati.

INDUSTRY

Biotechnology

A PRODUCT ORIC PHARMACEUTICALS, INC. IS KNOWN FOR

ORIC-944 (rinzimetostat)
ORIC-944 (rinzimetostat)

ORIC Pharmaceuticals' investigational oral drug, a selective allosteric PRC2 inhibitor, is in clinical-stage development for metastatic castration-resistant prostate cancer, with a Phase 3 trial planned for early 2026.

COMPETITORS

COMPETITOR
NVS COMPARE
PFE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
121
LISTED HERE
22
RANKED BY POSITION SIZE
XBI
0.40% · 3.5M
VTI
0.00% · 3.0M
IWM
0.03% · 1.9M
SCHA
0.02% · 385.6K
DFAS
0.03% · 334.2K
TMSL
0.14% · 311.2K
FESM
0.06% · 295.5K
AVSC
0.07% · 163.7K
LABU
0.27% · 126.6K
CANC
0.62% · 99.0K
XRS2.DE
0.03% · 70.9K
PRFZ
0.03% · 62.8K
OP
OPTZ
0.23% · 40.3K
BBC
0.99% · 37.9K
RSSL
0.03% · 35.5K
TILT
0.00% · 7.7K
RFLR
0.07% · 4.8K
ESSC
0.12% · 4.2K
BIB
0.05% · 3.7K
VETS
0.06% · 1.8K
USFMDN.MX
0.00% · 184
RESM
0.03% · 121

INSTITUTIONAL OWNERSHIP

SHARES OWNED
67.92%
HOLDERS
236
TOP 12 OF 236 · RANKED BY POSITION SIZE
Nextech Invest, Ltd.
7.2M sh · $77.57M
Blackrock, Inc.
6.8M sh · $73.9M
Ecor1 Capital, LLC
6.7M sh · $80.74M
Price T Rowe Associates Inc /Md/
6.6M sh · $71.67M
Vr Adviser, LLC
6.6M sh · $79.16M
Viking Global Investors LP
6.6M sh · $78.87M
Pfizer Inc
5.4M sh · $64.52M
Nextech Invest Ltd.
5.3M sh · $42.66M
State Street Corp
4.9M sh · $53M
Blackrock Inc.
4.8M sh · $34.15M
Svennilson Peter
4.8M sh · $119.25M
Vanguard Group Inc
4.7M sh · $55.8M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Piscitelli Dominic
Purchase · 25.0K shares
2026-08-26
★
OFFICER: CHIEF FINANCIAL OFFICER
Piscitelli Dominic
Purchase · 52.0K shares
2026-08-26
★
OFFICER: CHIEF FINANCIAL OFFICER
Piscitelli Dominic
Sale · 25.0K shares
2026-08-26
★
OFFICER: CHIEF FINANCIAL OFFICER
Piscitelli Dominic
Sale · 52.0K shares
2026-08-26

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 2
OVERWEIGHT 2
6 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citigroup BUY Wedbush OUTPERFORM Wells Fargo OVERWEIGHT JP Morgan OVERWEIGHT Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ELVN$57.86COMPARE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
ATAI$7.29COMPARE
PGEN$6.95COMPARE
NKTR$72.52COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE